Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Editas Medicine (EDIT)

Editas Medicine (EDIT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,538,049
  • Shares Outstanding, K 67,826
  • Annual Sales, $ 90,730 K
  • Annual Income, $ -115,980 K
  • 60-Month Beta 1.94
  • Price/Sales 27.58
  • Price/Cash Flow N/A
  • Price/Book 3.91
Trade EDIT with:

Options Overview

Details
  • Implied Volatility 79.42%
  • Historical Volatility 40.16%
  • IV Percentile 17%
  • IV Rank 15.55%
  • IV High 154.71% on 02/01/21
  • IV Low 65.55% on 08/25/20
  • Put/Call Vol Ratio 0.86
  • Today's Volume 872
  • Volume Avg (30-Day) 5,121
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 62,797
  • Open Int (30-Day) 62,494

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.85
  • Number of Estimates 6
  • High Estimate -0.73
  • Low Estimate -0.94
  • Prior Year -0.43
  • Growth Rate Est. (year over year) -97.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
31.85 +20.34%
on 05/19/21
38.70 -0.96%
on 06/14/21
+5.11 (+15.38%)
since 05/14/21
3-Month
29.35 +30.59%
on 05/11/21
49.17 -22.05%
on 03/22/21
-7.95 (-17.18%)
since 03/12/21
52-Week
26.50 +44.64%
on 06/15/20
99.95 -61.65%
on 01/08/21
+11.34 (+42.01%)
since 06/12/20

Most Recent Stories

More News
CRISPR (CRSP) Up on Positive New Gene Therapy CTX001 Data

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows consistent and sustained response to treatment in patients with transfusion-dependent beta thalassemia and sickle cell disease.

VRTX : 193.85 (+0.43%)
EDIT : 38.41 (+2.65%)
NTLA : 87.55 (+2.65%)
CRSP : 129.22 (+1.75%)
Editas Medicine Strengthens Executive Leadership Team to Advance Pipeline and Support Long-term Growth

Mark S. Shearman, Ph.D., joins as Chief Scientific Officer

EDIT : 38.41 (+2.65%)
Editas Medicine Presents Preclinical Data Supporting the Initiation of the EDIT-301 Phase 1/2 RUBY Clinical Trial for the Treatment of Sickle Cell Disease at the European Hematology Association Congress

Preclinical data demonstrated robust fetal hemoglobin (HbF) induction in erythroid progeny cells with no detection of off-target editing; cells showed reduced sickling and improved rheological behavior...

EDIT : 38.41 (+2.65%)
Why Is Editas (EDIT) Down 2.9% Since Last Earnings Report?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

EDIT : 38.41 (+2.65%)
First Week of June 18th Options Trading For Editas Medicine (EDIT)

Investors in Editas Medicine Inc saw new options become available this week, for the June 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the EDIT options chain...

EDIT : 38.41 (+2.65%)
Editas (EDIT) Q1 Earnings Miss Estimates, Revenues Beat

Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.

BMY : 67.02 (-0.48%)
EDIT : 38.41 (+2.65%)
NBRV : 1.4300 (-0.69%)
ASLN : 3.59 (+13.61%)
Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

EDIT : 38.41 (+2.65%)
Editas Medicine Announces First Quarter 2021 Results and Update

Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer

EDIT : 38.41 (+2.65%)
Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer

Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company's Executive Vice President and Chief Scientific Officer. Dr....

EDIT : 38.41 (+2.65%)
Editas: Q1 Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Editas Medicine Inc. (EDIT) on Wednesday reported a loss of $56.7 million in its first quarter.

EDIT : 38.41 (+2.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point 39.88
2nd Resistance Point 39.07
1st Resistance Point 38.24
Last Price 38.41
1st Support Level 36.60
2nd Support Level 35.79
3rd Support Level 34.96

See More

52-Week High 99.95
Fibonacci 61.8% 71.89
Fibonacci 50% 63.22
Fibonacci 38.2% 54.56
Last Price 38.41
52-Week Low 26.50

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar